Docetaxel
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castrate Resistant Prostate Cancer
Conditions
Metastatic Castrate Resistant Prostate Cancer
Trial Timeline
Jan 30, 2018 → Sep 30, 2025
NCT ID
NCT03737370About Docetaxel
Docetaxel is a phase 1 stage product being developed by Bayer for Metastatic Castrate Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03737370. Target conditions include Metastatic Castrate Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castrate Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03737370 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Castrate Resistant Prostate Cancer